Product Development
FDA seeks to dampen expectations on BrainStorm ALS therapy amid patient push for access
Mar 3, 2021 | 2:23 AM GMT
In the face of a social media campaign by patients advocating for the access to BrainStorm’s ALS therapy NurOwn, FDA took the highly unusual step of commenting on the results of a Phase III trial before